<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="548">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04371367</url>
  </required_header>
  <id_info>
    <org_study_id>2020-21</org_study_id>
    <nct_id>NCT04371367</nct_id>
  </id_info>
  <brief_title>Avdoralimab an Anti-C5aR Antibody, in Patients With COVID-19 Severe Pneumonia ( FORCE )</brief_title>
  <acronym>FORCE</acronym>
  <official_title>A Double-blind, Randomized Study Versus Placebo of Avdoralimab (IPH5401), an Anti-C5aR Antibody, in Patients With COVID-19 Severe Pneumonia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique Hopitaux De Marseille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Innate Pharma</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Assistance Publique Hopitaux De Marseille</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this trial is to improve the proportion of COVID-19 patients with
      severe pneumonia who no longer need to be hospitalized, and to reduce the need for and
      duration of mechanical ventilation in patients with COVID-19 pneumonia complicated by acute
      respiratory distress syndrome (ARDS).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 27, 2020</start_date>
  <completion_date type="Anticipated">October 27, 2020</completion_date>
  <primary_completion_date type="Anticipated">June 27, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Parallel Assignment</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Double (Participant, Investigator)</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients alive and no longer hospitalized at D14</measure>
    <time_frame>day 14</time_frame>
    <description>number of patients alive and discharged from the hospital at Day 14 for COVID-19 severe pneumonia patients who don't require hospitalization in ICU</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of ventilator-free days at Day 28 (VFD28)</measure>
    <time_frame>day 28</time_frame>
    <description>Number of days without mechanical ventilation at Day 28 for COVID-19 related Acute Respiratory Distress Syndrome (ARDS) Patients hospitalized in ICU</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-related adverse events</measure>
    <time_frame>day 28</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">108</enrollment>
  <condition>COVID</condition>
  <arm_group>
    <arm_group_label>avdoralimab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Biological/Vaccine: avdoralimab intravenous administration of avdoralimab
Other Names:
• IPH5401</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>intravenous administration of Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>avdoralimab</intervention_name>
    <description>intravenous administration of avdoralimab</description>
    <arm_group_label>avdoralimab</arm_group_label>
    <other_name>IPH5401</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>intravenous administration of placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  COVID-19 hypoxemic pneumonia defined by : Need for oxygen therapy ≥ 5 l/min to
             maintain SpO2 &gt; 93%

          -  For patients included in intensive care : Patient under mechanical invasive
             ventilation with a PaO2/FiO2 ratio &lt; 300 for more than 24 hours.

        Exclusion Criteria:

          -  Pregnant woman

          -  Uncontrolled sepsis of bacterial or fungal origin
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Emilie Garrido-Pradalie</last_name>
    <role>Study Director</role>
    <affiliation>Assistance Publique Hôpitaux de Marseille</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nicolas, SCHLEINITZ, MD</last_name>
    <phone>04-91-38-87-62</phone>
    <phone_ext>+33</phone_ext>
    <email>nicolas.schleinitz@ap-hm.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Julien CARVELLI</last_name>
    <phone>06.23.52.63.29</phone>
    <phone_ext>+33</phone_ext>
    <email>julien.carvelli@ap-hm.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Assistance Publique Hôpitaux de Marseille</name>
      <address>
        <city>Marseille</city>
        <zip>13354</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julien CARVELLI, MD</last_name>
      <phone>04 13 42 96 37</phone>
      <phone_ext>+33</phone_ext>
      <email>julien.carvelli@ap-hm.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 29, 2020</study_first_submitted>
  <study_first_submitted_qc>April 30, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 1, 2020</study_first_posted>
  <last_update_submitted>April 30, 2020</last_update_submitted>
  <last_update_submitted_qc>April 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

